Skip to Content

Myxredlin Approval History

FDA Approved: Yes (First approved June 20, 2019)
Brand name: Myxredlin
Generic name: insulin human in sodium chloride
Dosage form: Injection
Company: Baxter International Inc.
Treatment for: Diabetes, Type 1, Diabetes, Type 2

Myxredlin (insulin human in sodium chloride) is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Development History and FDA Approval Process for Myxredlin

Jul 22, 2019Approval Baxter Announces U.S FDA Approval of Myxredlin, the First and Only Ready-To-Use Insulin for IV Infusion

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.